the to provide fourth to we enter platform strongest updates HOPE-X our joining for on of and and we we balance accomplishments with Therapeutics programs. update ever I am company. progress our you quarter on I'm as these all I deal the a full-year position today been are and will thank strong and Today, XXXX. technology XX:XX in of that Capricor growing you sheet, our exosomes the Nippon have afternoon, launching Good delighted you conference and XX:XX call. pleased Shinyaku say as
platform. distinct is you developing As two Capricor know
First, pivotal also late-stage fight a Duchenne cell Phase X potential and our is investigated COVID-XX. against is therapy the CAP-XXXX being a for entering study Dystrophy, clinical as therapy program Muscular and
we with more Second, an exosomes, them molecules, for we are harnessing a different engineering nature's platform other the targeted of payloads vehicle RNAs, delivery are delivery of and payloads. potentially exosome power and efficient proteins small developing where
of deliver pursuing We these have capital partnerships, are and fronts. advancing a successfully validate with XX:XX of focused assembled have in build to of development. on on DMD platforms efficient both both as the continue we use expedite to team to done product We world-class and these
and Diego, focused are on efficient to strategy these thus company's world's We major headquarters the well. achieving recently California to objectives off. paid far highly as and one and San of has the talent then We biotechnology hubs attract being this capital relocated
continue trial, City all We is build with as President management and Pharma, X, and products Kite has X biologics, Clinical and have XX:XX and that spent Kite's in she the Development. President as for us Yasmine X platform therapy development the as for where capabilities of the management and she where end, development well will career a cell facilities of Hope, manufacturing in the manufacturing, building all clinical after systems Phase Dan to experience at global activities. was from XX-years in both Bayer responsible she Vice years charge appointment clinical the exosome for oversight HOPE-X GMP head our clinical of also the of medicine. at was Daniel autologous Sanofi Then development for of to of commercial key drug plans CAP-XXXX. vector is background We sites of of as many Her comes she ready and commercial potential registration products. for of Dr. be line announced Ms. goals just a our of technology. in of was CAP-XXXX. approximately towards we team Paulson, XX:XX Shad the to building CAP-XXXX quality manufacturing Recently, conduct her recruiting joined Vice of as Dan is out enhance in building and directly quality experience of our to of Quality Yasmine GXP
the in DMD. opportunities Remind program rare which a in DMD upfront partnering for outside throughout the as their will me approved the to Pfizer, just such alliances and commercialization agreement we dollars our pharmaceutical for executives Shinyaku past progress an team history company recruit sales. the in for the secured of a Nippon coupon Nippon based States. pediatric a more payments rights Asia sales-based would as a ability to Johnson and product the these milestone shift Europe, approval partnership few. meaningful headquartered for let pursue have Shinyaku, which million with potential and already companies your XX:XX entered rights. regulatory from on and at market to in qualify Johnson agreement milestone a other with provide has revenue XX:XX commercialization As & $XX and on developed Kyoto, commercialization. Importantly, States this announced, X,XXX healthy of bring is additional a fully of Our opportunities. you million a employees We on push stream has CAP-XXXX with States, solely clinical, and for United Capricor to we $XXX towards DMD as commercial up high US maintains payments, to United and to These name exciting over United voucher Capricor. plus Capricor, This CAP-XXXX product to in in capital are and Now continue performing for we attention all distribution Capricor’s reflective milestones, have and now have Japanese in Japan of XX:XX we into we XXX-year the markets. our potentially, territories
sites Phase are clinical our to a as placebo-controlled First in proceed double-blind, a HOPE-X United States. studies. XX standpoint X across from we a the XX approximately enroll regulatory designed clear to clinical plan HOPE-X study randomized, with to XX patients
be treating will therapeutic the underway population of few and in stages the startup disease one-half DMD terms and currently largely study. At very This this in are non-ambulant comprises process the over of market. exist. We we patient of well the who options for XX:XX selection activities for later site whom are time, patients
subject the Our goal in quarter XXXX. first is of to second the treat
I'm with in built begin interim Once is chances to share the assure X at for Phase sample we will in size clinical this order We we that tiered you provide journal. to peer-reviewed updates patients, best analysis HOPE-X also as trial have HOPE-X progresses. trial. also our success treat for for the Today, to publication slated re-estimation pleased pre-specified top XX:XX a of
We embargo, strict under stay are please tuned so for a published. is updates more it when
a our the because HOPE-X strength results been in stringent publication. pure tier data in goal top have believe was that messaging we the review that of to publish We journal, of the warranted
And that and of and XX:XX the methods, the potential We of It tier these mechanism analysis, peer-reviewed process XX:XX of the showing have journals publication. to we carefully have all achieved scrutinized acceptance review has help data is the clinical that rigorous occurs data, actions data review require. because supported important paper when trial collection for only and the and clinical proposed the the pre-clinical conduct data goal. determined drive the high our now journal is believe and of been quality been be a Additionally, action. data of proteomic the acceptance mechanism top
so as And course robust also, evidence from an supports only skeletal clinical Of review the the length far. Remind together, function causes in in has peer-reviewed you measured of living is program therapeutic that one the by treatments careful trial journal. of and tested but and of in may by in may importantly CAP-XXXX the aspect Taken very now not thus the support ejection with as cardiomyopathy fraction not of strong position and a to this We begin XX:XX showing the this impact death successful primary DMD. of delaying our of stellar of demonstrated HOPE-X, is these patients leading in effective seen potentially benefits DMD, well improve in the knowledge, community, important of decline who’ve affecting improvement towards which of DMD. DMD, result quality cardiac for DMD. CXAP-XXXX pivotal DMD most any been our CAP-XXXX DMD, as muscle life the X:XX working the as people with having a the and DMD validation the patients, life
having our now the with to towards to for registration want we CAP-XXXX. that XX:XX an continue but dose will means trial single patients, support to and XX patients. in randomized I COVID-XX, yet of not a commercialization yet which the and end, are So you ventilation. critical to using INSPIRE, work as with patients trial investigators clinical CAP-XXXX on I but update they provide COVID-XX breathing, the their difficulty severe severe, thank treat families are requiring This of not that
few analysis in had treating track patients. quarter having data sets of While and database the The have options still primary has based still receive first COVID, this And timeline in the day. we on endpoint We remain a XXXX. to of stages FDA approximately plan of safety for XX:XX of group in lot of the few weeks. XX-day to lock made and by over are we a next mandated per this the progress are available trial on we average very deaths particular data final and for the data end as been on by there the X,XXX US, that
highly rights XX:XX we to tuned you in respect platform this Please steps So this time in development. we to FDA technology. I this to updates, retain our this discuss that meet now with like will exosome next remind effectiveness program. stay to would with CAP-XXXX needed evolves. for program Moving demonstrate population, all clinical at as to patient plan
we were using quality have manufacturing the the actively as have of meatus, of production feedback pre-IND for vaccine preclinical from on and products. of as of this deliver proteins. XXXX, external the types which multiple of that bivalent significantly payloads, mRNA have advance payloads, Over the well exosome on exosomes end, as been published ability mRNA, exosome data, even scaling able working focusing as exosomes COVID-XX we to delivery FDA we xiRNAs had for as well as assured as for they well at outlining based such at have have the to As positive on well using XX:XX fine-tuning the previously development different our point, we mRNAs, fact exosomes To IND targeting vehicles as the platform discussed have and including a based although therapeutics. course into development in -up further clinic. vaccines to hold Therefore, for vaccines build major mRNA rather of XX:XX morbidity they this significant XX:XX development COVID and the preventing including filing off limitations, of and of we substantial roadmap vaccine the will on are than effective described the an this resources of and the opportunities However, COVID pipeline the mRNA to clinic invest decided markets our further saturated investing and vaccine mortality. with market another time, resources exosome a next-generation indications our platform and bringing at current and
As developed, our clinical have specific choose technology. will directions that on platform more we exosome our color the platform we for
commercial pursuit strive exosomes various Capricor deliver of opportunity of presents goal for Capricor on Muscular will the Duchenne our you. extended commitment a programs cash And drug to be and our detailed the that over the well for million patients a pipeline committed also a execute supported develop have the to for as two belief develop on CFO other unique is We Our indications. positioned XX:XX from for would expected I to we runway $X across in million on cash, Dystrophy remain and fronts, that or Bergmann, be independently. we closing, and call This delivery. potential suffer The our and more XX:XX our for now partnering the CAP-XXXX those these Shinyaku. our future has for financials. $XX far position which begin AJ from factors Nippon payment in will update turn to to helping into In Thank indications upfront XXXX, XX:XX XXXX. diseases. world, approximately
